Cardiac-specific antigens

Carboxyfluorescein 1467, 1480 Carcinoembryonic antigen 1123, 1234, 1277 Cardiac specific proteins 290 Cardiac transcription factors 290, 293 Cardiac troponin 293 Cardiomyocytes 289, 320... 

Antigen retrieval lipofusion-artifact may appear as granule staining in liver and cardiac tissue, or as specific staining in pancreatic sections. 

In 1986, Muromonab CD-3 (OKT-3), which is a monoclonal antibody was first introduced to clinical practice, and the agent has been effective in reversing corticosteroid-resistant acute rejection in renal, liver, and cardiac transplant recipients. OKT-3 is administered only by intravenous injection and has a harmonic half-life of approximately 18 h. It binds specifically to the CD-3 complex, which is involved in antigen recognition and cell stimulation, on the surface of T lymphocytes. Immediately after administration, CD-3-positive T lymphocytes are abruptly removed from the circulation. OKT-3 may be removed by opsonization by the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production [230]. 

Some products are manufactured using methods that reduce the risk of calcification following implantation. These anticalcifications are commonly used in cardiac and vascular products such as peripheral vascular grafts and bioprosthetic heart valves where calcification has significant impact on long-term outcomes. In some instances, specific ceU/tissue antigens may be removed via specific chemical treatment. For... 

---